Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CogstateASX:CGS +2.19%80 3-Year Book Growth Rate is 17.30% as of Dec. 2025, which is 204% above its 10-year median of 5.70. GuruFocus rates ASX:CGS with a GF Score™ of 80/100 and a GF Value™ of A$2.10 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 581 Healthcare Providers & Services companies, Cogstate ranks better than 74.7% on this metric.
During the past 12 months, Cogstate's average Book Value per Share Growth Rate was 11.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 17.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 26.60% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 16.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Cogstate was 43.80% per year. The lowest was -40.60% per year. And the median was 5.70% per year.
Cogstate (ASX:CGS) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Cogstate 3-Year Book Growth Rate Related Terms
ASX:CGS vs VEEV, BTSG, HQY: 3-Year Book Growth Rate Comparison
For the Health Information Services subindustry, Cogstate's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate 3-Year Book Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Cogstate's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 17.30% mean?
Cogstate (ASX:CGS) has a 3-Year Book Growth Rate of 17.30% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cogstate and its competitors. This is 204% above median its historical median of 5.70. According to the industry distribution chart, Cogstate ranks #147 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 25.3%.
Is Cogstate's 3-Year Book Growth Rate too high?
Cogstate's current 3-Year Book Growth Rate of 17.30% is 204% above median its 10-year median of 5.70. The Healthcare Providers & Services industry median 3-Year Book Growth Rate is 5.50. Cogstate's value of 17.30% is 214.5% above this industry median. Based on the distribution chart, Cogstate ranks #147 out of 581 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cogstate has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's 3-Year Book Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #147 out of 581 companies for 3-Year Book Growth Rate. This puts Cogstate in the upper half of its industry. The industry median 3-Year Book Growth Rate is 5.50. Cogstate's value of 17.30% is 214.5% above this benchmark. While the company's 10-year median is 5.70 vs. the industry median of 5.50, Cogstate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Healthcare Providers & Services company?
The median 3-Year Book Growth Rate among Healthcare Providers & Services companies is 5.50, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current 3-Year Book Growth Rate of 17.30% is 214.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cogstate and its competitors. For the Healthcare Providers & Services industry, the median 3-Year Book Growth Rate is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current 3-Year Book Growth Rate is 17.30%, which is 204% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.10, compared to a current price of A$2.80 — trading 33.3% above its estimated fair value. The current 3-Year Book Growth Rate is 17.30%, which is 204% above median its 10-year median of 5.70 and 214.5% above the Healthcare Providers & Services industry median of 5.50. Cogstate's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current 3-Year Book Growth Rate is 17.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (ASX:CGS) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of A$2.80 is trading 33.3% above its estimated GF Value™ of A$2.10.
GuruFocus considers Cogstate to be Significantly Overvalued.
Key valuation signals for ASX:CGS:
3-Year Book Growth Rate: 17.30% (204% above median its 10-year median of 5.70)
GF Value™: A$2.10 vs. price of A$2.80 (33.3% above fair value)
Industry Position: 214.5% above the Healthcare Providers & Services median (#147 of 581)
No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
80GF Score
Get the complete analysis for ASX:CGS
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGS has been successfully added to your 
